hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Genealogical === The term bloodline is used in genealogy to refer to one's ancestry, origins, and ethnic background. Other terms where blood is used in a family history sense are blue-blood, royal blood, mixed-blood and blood relative.
In December 2024, research commissioned by the UK recycling charity Material Focus estimated that 13 vapes were being thrown away every second in the UK, amounting to over a million per day, and that approximately 8.2 million vapes a week were discarded or recycled incorrectly, with growth linked to larger "big puff" devices. Research led by University College London and the University of Oxford reported that lithium-ion cells inside some disposable vapes can retain high capacity after hundreds of charge-discharge cycles, underscoring resource waste and the importance of proper collection and recycling of embedded batteries. Recycling challenges, waste issues, and fire hazards are cited. Concerns about youth vaping are also raised. The UK Vaping Industry Association defends disposables as quitting aids and warns of potential black market products if banned. Although some brands have begun recycling services for their e-cigarette cartridges and batteries, the prevalence of recycling is unknown. A 2024 UK study reported that only a minority of surveyed retailers provided recycling points despite existing legal obligations, and estimated that more than 250 million disposable vapes could be discarded before regulatory restrictions came into force. Several jurisdictions subsequently moved to restrict or ban single-use (disposable) vapes while allowing reusable products, citing environmental and waste concerns. In Australia, imports of disposable vapes were prohibited from 1 January 2024 under new import controls.
=== Controlled-release formulations === Controlled or modified-release formulations are designed to deliver medications at a steady rate over time, helping maintain consistent drug levels in the bloodstream. This steady release reduced how often patients need to take their medication and minimizes the ups and downs in drug concentration that can cause side effects or lower effectiveness. These systems often take the form of matrix tablets, osmotic pumps, and reservoir-type devices, all of which use physical or chemical barriers to regulate how the drug is released. This approach is especially useful for chronic conditions such as high blood pressure, diabetes, or chronic pain, where maintaining stable therapeutic levels is key to keeping symptoms under control. The concept of controlled-release medication dates back to the 1950s, when Dexedrine became the first such formulation on the market. This era saw the introduction of transdermal patches, which deliver drugs slowly through the skin. As technology progressed, new formulations were developed to match the specific properties of different drugs. Examples include long-acting depot injections for medication like antipsychotics and hormone therapies, which remain effective for weeks or even months after a single dose. Since the late 1990s, research has increasingly turned to nanotechnology as a way to improve controlled-released drug delivery.
== History == In 1988, Stark introduced an "Ethics in Patient Referrals" bill concerning physician self-referrals. Some of the ideas in the bill became law as part of the Omnibus Budget Reconciliation Act of 1990. In specific, what is referred to as "Stark I" prohibited a physician referring a Medicare patient to a clinical laboratory if the physician or his/her family member has a financial interest in that laboratory. It was codified in the United States Code, Title 42, Section 1395nn (42 U.S.C. 1395nn, "Limitation on certain physician referrals"). The Omnibus Budget Reconciliation Act of 1993 contained what is known as "Stark II" amendments to the original law. "Stark II" extended the "Stark I" provisions to Medicaid patients and to DHS other than clinical laboratory services. The Centers for Medicare and Medicaid Services has issued rules in the Federal Register to implement Stark Law, including a 2001 "Phase I" final rule, a 2004 "Phase II" interim final rule, and a 2007 "Phase III" final rule.
Sources: en.wikipedia.org
Kava reduces short-term, situational anxiety, but its specific efficacy for generalized anxiety disorder appears to not be supported by the evidence. Many countries banned or restricted kava in 2002 due to safety concerns. The World Health Organization (WHO) subsequently reviewed kava's safety and concluded that moderate consumption of kava in its traditional form, as a water-based suspension of roots, presents an "acceptably low level of health risk". However, WHO and other health authorities have also concluded that consumption of kava extracts produced with organic solvents or excessive amounts of low-quality kava products may be linked to an increased risk of adverse health outcomes, including liver injury.
=== IBP Golden Pillar of Law Award === Duterte was conferred the Golden Pillar of Law Award on September 15, 2025, from the Davao City chapter of the Integrated Bar of the Philippines (IBP). Human rights lawyers and activists urged the IBP to revoke the award viewing that his role in the war on drugs contradicts with the spirit of the recognition. The national office of the IBP maintained Duterte's presumed innocence as it "do not confer guilt or grace beyond the reach of law" but nevertheless pledge to review rules concerning the award. IBP Davao insist that Duterte satisfy the criteria for the award based on professional longevity and standing status and that the Golden Pillar award does not "serve as an endorsement of political acts or personal ideologies".
AI has a significant carbon footprint due to growing energy consumption from both training and usage. Scientists and journalists have expressed concerns about the environmental impact that the development and deployment of generative models are having: high CO2 emissions, large amounts of freshwater used for data centers, high amounts of electricity usage, electronic waste, and pollution due to backup diesel generator exhaust. There is also concern that these impacts may increase as these models are incorporated into widely used search engines such as Google Search and Bing, as chatbots and other applications become more popular, and as models need to be retrained. The carbon footprint of generative AI globally is estimated to be growing steadily, with potential annual emissions ranging from 18.21 to 245.94 million tons of CO2 by 2035, with the highest estimates for 2035 nearing the impact of the United States beef industry on emissions (currently estimated to emit 257.5 million tons annually as of 2024).
Sources: en.wikipedia.org
== Mechanism == The reaction catalyzed by this enzyme proceeds via a ping-pong mechanism by using 2 equivalents of NAD(P)H to reduce one equivalent of the azo compound substrate (for example methyl red where Ar = p-dimethylaniline and Ar' = o-benzoic acid) into two equivalents of aniline product:
Arteries form part of the circulatory system. They carry blood that is oxygenated after it has been pumped from the heart. Coronary arteries also aid the heart in pumping blood by sending oxygenated blood to the heart, allowing the muscles to function. Arteries carry oxygenated blood away from the heart to the tissues, except for pulmonary arteries, which carry blood to the lungs for oxygenation (usually veins carry deoxygenated blood to the heart but the pulmonary veins carry oxygenated blood as well). There are two types of unique arteries. The pulmonary artery carries blood from the heart to the lungs, where it receives oxygen. It is unique because the blood in it is not "oxygenated", as it has not yet passed through the lungs. The other unique artery is the umbilical artery, which carries deoxygenated blood from a fetus to its mother. Arteries have a blood pressure higher than other parts of the circulatory system. The pressure in arteries varies during the cardiac cycle. It is highest when the heart contracts and lowest when heart relaxes. The variation in pressure produces a pulse, which can be felt in different areas of the body, such as the radial pulse. Arterioles have the greatest collective influence on both local blood flow and on overall blood pressure. They are the primary "adjustable nozzles" in the blood system, across which the greatest pressure drop occurs.
=== Paleochemotaxonomy === In the field of paleochemotaxonomy the presence of biogenic substances in geological sediments is useful for comparing old and modern biological samples and species. These biological markers can be used to verify the biological origin of fossils and serve as paleo-ecological markers. For example, the presence of pristane indicates that the petroleum or sediment is of marine origin, while biogenic material of non-marine origin tends to be in the form of polycyclic compounds or phytane. The biological markers also provide valuable information about the degradation reactions of biological material in geological environments. Comparing the organic material between geologically old and recent rocks shows the conservation of different biochemical processes.
==== Astronomy ==== In astronomy, in situ measurement involves collecting data directly at or near a celestial object using spacecraft or instruments physically present at the location. For example, the Parker Solar Probe conducts in situ studies of the Sun's atmosphere, while the Cassini–Huygens mission similarly analyzed Saturn's magnetosphere. In situ formation refers to astronomical objects that formed at their current locations without significant migration. Some theories propose that planets, such as Earth, formed in their present orbits rather than moving from elsewhere. Star clusters may form within their host galaxy, rather than being accreted from external sources.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.